首页> 外文期刊>Diabetes/metabolism research and reviews >Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.
【24h】

Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.

机译:胰高血糖素样肽1(GLP-1)的结构和功能研究:设计用于治疗糖尿病的新型药理剂。

获取原文
获取原文并翻译 | 示例
           

摘要

Glucagon-like peptide-1 (GLP-1) is a proglucagon-derived peptide secreted from gut endocrine cells in response to nutrient ingestion. The multifaceted actions of GLP-1 include the following: (1) the stimulation of insulin secretion and of its gene expression, (2) the inhibition of glucagon secretion, (3) the inhibition of food intake, (4) the proliferation and differentiation of beta cells, and (5) the protection of beta-cells from apoptosis. The therapeutic utility of the native GLP-1 molecule is limited by its rapid enzymatic degradation by a serine protease termed dipeptidyl peptidase-IV (DPP-IV). The present article reviews the research studies aimed at elucidating the biosynthesis, metabolism, and molecular characteristics of GLP-1 since it is from these studies that the development of a GLP-1-like pharmacological agent may be derived.
机译:胰高血糖素样肽-1(GLP-1)是响应营养物摄入从肠内分泌细胞分泌的胰高血糖素衍生肽。 GLP-1的多方面作用包括:(1)刺激胰岛素分泌及其基因表达;(2)抑制胰高血糖素分泌;(3)抑制食物摄取;(4)增殖和分化(5)保护β细胞免于凋亡。天然GLP-1分子的治疗用途受到称为二肽基肽酶-IV(DPP-IV)的丝氨酸蛋白酶的快速酶促降解的限制。本文综述了旨在阐明GLP-1的生物合成,代谢和分子特征的研究,因为从这些研究中可以衍生出类似GLP-1的药理剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号